Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Hypertension and Related Complications
share announcement

Advances in Hypertension and Related Complications

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 1152

Special Issue Editors

Dr. Thenral Socrates

E-Mail Website
Guest Editor
Medical Outpatient Department and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
Interests: hypertension; hypertensive disorders in pregnancy; postpartum hypertension; cardiovascular risk in women
Dr. Thilo Burkard

E-Mail Website
Guest Editor
1. Medical Outpatient Department and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
2. Department of Cardiology, University Hospital Basel, 4031 Basel, Switzerland
Interests: hypertension; pharmacotherapy; resistant hypertension; preventive cardiology; hypertensive heart disease; chronic disease managementment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hypertension, a public health challenge affecting approximately 1.13 billion people globally, has experienced significant advancements in both its management and the understanding of its associated comorbidities. It is a leading cause of cardiovascular diseases, contributing to an estimated 10.4 million deaths annually. The prevalence of hypertension continues to rise, particularly in low- and middle-income countries, where approximately two-thirds of cases are reported, highlighting the urgent need for innovative and effective solutions.

Pharmacological innovations have been particularly noteworthy. The advent of new antihypertensive agents, alongside combination therapies, has demonstrated enhanced efficacy and safety profiles, resulting in superior blood pressure control and a diminution in cardiovascular events. Concurrently, lifestyle modifications, encompassing dietary adjustments and augmented physical activity, continue to be integral components of hypertension management due to their substantial impact on blood pressure regulation.

The intricate relationship between hypertension and its comorbidities, such as chronic kidney disease, hypertensive heart disease, heart failure, and diabetes, remains a focal point of contemporary research. Insights into these interconnections have spurred the development of novel treatments targeting these conditions, thereby improving patient prognoses.

This Special Issue endeavors to publish scientific articles that elucidate the advancements in the field, with an emphasis on mitigating the incidence and severity of hypertension-related complications. Topics of particular interest include methodologies for detection, novel therapeutic approaches, treatment paths, and strategies for managing the complex interplay between hypertension and other chronic conditions. By disseminating these advancements, this publication aims to enhance clinical practices and ultimately reduce the global burden of hypertension and its associated complications.

Dr. Thenral Socrates
Dr. Thilo Burkard
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypertension
  • hypertensive disorders of pregnancy
  • antihypertensive therapy
  • resistant hypertension
  • dual endothelin receptor antagonist
  • renal denervation
  • cardiovascular risk
  • adherence
  • kidney disease
  • secondary hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1903 KiB  
Article
Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews
by Kannan Sridharan and Gowri Sivaramakrishnan
J. Clin. Med. 2025, 14(4), 1097; https://doi.org/10.3390/jcm14041097 - 8 Feb 2025
Viewed by 936
Abstract
Background: Amlodipine has recently been incidentally reported with angioedema and is frequently prescribed with renin–angiotensin–aldosterone system inhibitors (RAAS-i) for hypertension management. While RAAS-i drugs are known to cause angioedema, the risk associated with amlodipine alone or in combination with RAAS-i drugs remains unclear. [...] Read more.
Background: Amlodipine has recently been incidentally reported with angioedema and is frequently prescribed with renin–angiotensin–aldosterone system inhibitors (RAAS-i) for hypertension management. While RAAS-i drugs are known to cause angioedema, the risk associated with amlodipine alone or in combination with RAAS-i drugs remains unclear. This study aimed to evaluate the association between amlodipine use and angioedema using pharmacovigilance data. Methods: We analyzed adverse event reports from the US FDA Adverse Event Reporting System using both frequentist and Bayesian approaches. Drug–drug interactions were assessed using multiplicative models. Additionally, we conducted a systematic review of published case reports of amlodipine-associated angioedema. Results: Among 29,661,136 reports, 2076 cases of angioedema were identified (1067 with amlodipine alone, 1009 with amlodipine–RAAS-i combinations). Significant safety signals were detected for amlodipine alone and in combination with aliskiren, specific ACE inhibitors (quinapril, benazepril, trandolapril, fosinopril, perindopril), and certain ARBs (candesartan, losartan). No significant interactions were observed between amlodipine and RAAS-i drugs except for the amlodipine–trandolapril combination. A review of published cases demonstrated definite causality in two cases and possible association in others, with most patients presenting with oropharyngeal/facial edema and achieving complete recovery following drug discontinuation and standard therapy. Conclusions: Our findings suggest a potentially increased risk of angioedema with amlodipine, both as monotherapy and in specific RAAS-i combinations. While these results should not discourage appropriate clinical use, they emphasize the importance of monitoring for angioedema, particularly during therapy initiation. The findings from this study need to be validated in prospective studies for further elucidation of the underlying mechanisms. Full article
(This article belongs to the Special Issue Advances in Hypertension and Related Complications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop